Company

Protara Therapeutics, Inc.

Protara Therapeutics develops treatments for cancer and rare diseases.

About

Protara's clinical pipeline includes TARA-002, being evaluated for bladder cancer and lymphatic malformations, and IV Choline Chloride for intestinal failure-associated liver disease. Founded in 2017 and based in New York, the company trades on Nasdaq as TARA. It raised USD 45 million in private placement financing in April 2024.

1Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in